Literature DB >> 2271371

Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.

L D Lewis1, D L Fitzgerald, P G Harper, H J Rogers.   

Abstract

1. Fifteen patients received 1.5 g m-2 of ifosfamide intravenously over 0.5 h every day for 5 days. Twenty-one courses of treatment were studied. Plasma was assayed for ifosfamide by gas liquid chromatography and plasma alkylating activity was measured using the nitrobenzylpyridine (NBP) reaction. 2. A pharmacokinetic analysis revealed a significant decrease in the median (range) elimination half-life of ifosfamide from 7.2 (2.8-14.2) h on day 1 to 4.6 (2.3-7.7) h on day 5 (P less than 0.001, Wilcoxon's test) with a concomitant significant increase in the median (range) clearance from 66 (31-148) ml min-1 on day 1 to 115 (52-381) ml min-1 on day 5 (P less than 0.001). There was no significant change in the volume of distribution on day 5 compared with day 1. 3. There was a highly significant 223% increase in the median (range) plasma nitrobenzylpyridine alkylating activity area under the curve on day 1 from 16 (0.6-105) nmol nor nitrogen mustard equivalents ml-1 h to 52 (13-238) nmol nor nitrogen mustard equivalents ml-1 h on day 5. 4. During five courses of treatment (in five patients in the group) 24 h urine samples were collected on days 1 and 5. The median (range) renal clearance of ifosfamide on day 1 was 6.8 (1.3-16.2) ml min-1 compared with 5.7 (1.3-15.3) ml min-1 on day 5. This difference was not significant. The median (range) metabolic clearance of ifosfamide in these five patients on day 1 was 78.6 (39.9-141.2) ml min-1 and 132.6 (54.6-149.5) ml min-1 on day 5.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2271371      PMCID: PMC1368173          DOI: 10.1111/j.1365-2125.1990.tb03842.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Pharmacokinetics of divided-dose ifosfamide.

Authors:  R L Nelson; L M Allen; P J Creaven
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

2.  Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).

Authors:  P J Creaven; L M Allen; M H Cohen; R L Nelson
Journal:  Cancer Treat Rep       Date:  1976-04

3.  [Experiences with N-Lost phosphamide esters].

Authors:  P Drings; R Allner; N Brock; H Burkert; M Fischer; E Fölsch; H Gerhartz; P Götzky; I Hoppe; G Kanzler; H O Klein; K Mainzer; H Martin; P Obrecht; G Palme; H Paulisch; H Riegg; J C Schubert; U Treske; W Weise; D Willems; H Wilmanns; S Witte; H Wohlenberg
Journal:  Dtsch Med Wochenschr       Date:  1970-03-06       Impact factor: 0.628

4.  Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.

Authors:  D L Hill; W R Laster; M C Kirk; S el-Dareer; R F Struck
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

5.  Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.

Authors:  R A Alarcon; J Meienhofer; E Atherton
Journal:  Cancer Res       Date:  1972-11       Impact factor: 12.701

6.  Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

7.  Decreased hepatic drug demethylation in patients receiving chemo-immunotherapy.

Authors:  A Lipton; G W Hepner; D S White; H A Harvey
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

8.  Decreased half life of cyclophosphamide in patients under continual treatment.

Authors:  M D'Incalci; G Bolis; T Facchinetti; C Mangioni; L Morasca; P Morazzoni; M Salmona
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

9.  Studies of the effects of cyclophosphamide, vincristine, and prednisone on some hepatic oxidations and conjugations.

Authors:  H L Gurtoo; T Gessner; P Culliton
Journal:  Cancer Treat Rep       Date:  1976-09

10.  Reduction of ifosfamide toxicity using dose fractionation.

Authors:  V Rodriguez; G P Bodey; E J Freireich; K B McCredie; E M McKelvey; C K Tashima
Journal:  Cancer Res       Date:  1976-08       Impact factor: 12.701

View more
  14 in total

1.  Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Authors:  T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

4.  Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

Authors:  S A Corlett; D Parker; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 5.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 6.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

7.  Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.

Authors:  C P Granvil; J Ducharme; B Leyland-Jones; M Trudeau; I W Wainer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.

Authors:  V Kurowski; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Ifosfamide enantiomers: pharmacokinetics in children.

Authors:  V K Prasad; S A Corlett; K Abaasi; D Heney; I Lewis; H Chrystyn
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.